Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy

EJNMMI Research

Table 2 Survival analysis demonstrating association between clinical stage, Gleason score, PSA, BSI and survival

Variable	No. of patients	Hazard ratio	P value
Univariate analysis
Clinical T stage	129	1.53 (1.17 to 1.99)	0.002
Gleason score	127	1.39 (1.10 to 1.76)	0.006
PSA	130	1.0003 (1.0001 to 1.0005)	0.001
BSI	130	1.21 (1.14 to 1.28)	< 0.001
Multivariate analysis
Clinical T stage	126	1.34 (1.02 to 1.77)	0.04
Gleason score	126	1.36 (1.07 to 1.73)	0.01
PSA	126	1.0003 (1.0001 to 1.0005)	0.006
Multivariate analysis
Clinical T stage	126	1.17 (0.87 to 1.57)	0.29
Gleason score	126	1.37 (1.07 to 1.75)	0.01
PSA	126	1.0000 (0.9998 to 1.0003)	0.57
BSI	126	1.19 (1.12 to 1.28)	< 0.001